Cadrenal Therapeutics Inc CVKD
$1.61 $0.02 (1.26%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
CVKD Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Cadrenal Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Cadrenal Therapeutics Inc. Stock Analysis CVKD
United States Health Care Nano Cap Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. The company is headquartered in Ponte Vedra, Florida and currently employs 5 full-time employees. The company went IPO on 2023-01-20. The company has three clinical-stage assets: VLX-1005, a first-in-class Phase 2 12-LOX Inhibitor for patients with HIT; tecarfarin, an oral vitamin K antagonist (VKA) for chronic use in patients with kidney dysfunction or left ventricular assist devices (LVADs), and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. Its product candidate, tecarfarin, is a late-stage, reversible oral VKA in the same drug class as warfarin, designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Its frunexian is a small molecule fast-on, fast-off parenteral Phase II-ready potent intravenous (IV) Factor XIa inhibitor designed for acute care settings, especially where contact activation of coagulation by medical devices or artificial surfaces plays a significant role.
Cadrenal Therapeutics Inc (CVKD) Chart
Financial Metrics & Statements of Cadrenal Therapeutics Inc (CVKD)
FAQ's for Cadrenal Therapeutics Inc (CVKD)
- As of August 2026, Cadrenal Therapeutics Inc CVKD is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Cadrenal Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Cadrenal Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Cadrenal Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Cadrenal Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Cadrenal Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Cadrenal Therapeutics Inc (CVKD)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
